Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.
Number of employees : 204 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Flagship Pioneering ||38,506,526||
|Fidelity Management & Research Co. LLC ||13,527,493||
|David R. Epstein ||4,870,012||
|Baillie Gifford & Co. ||4,693,832||
|Invus Public Equities Advisors LLC ||4,633,791||
|The Vanguard Group, Inc. ||3,125,566||
|ARCH Venture Partners LLC ||2,618,351||
|SSgA Funds Management, Inc. ||2,440,295||
|JPMorgan Investment Management, Inc. ||1,634,116||
|Victory Capital Management, Inc. (Investment Management) ||1,572,187||
|Company contact information|
Rubius Therapeutics, Inc.
399 Binney Street
Cambridge, MA 02139
Phone : +1.617.679.9600
Web : http://www.rubiustx.com
Sector Bio Therapeutic Drugs
Connections : Rubius Therapeutics, Inc.